Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain
Brief Summary:
This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.
During the course of this study, each participant will take a daily dose of 20 mg of ABX-1431 or a matching placebo for approximately 7 to 9 weeks.